Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.

Hafström, L; Rudenstam, C. M.; Blomquist, Erik; Ingvar, Christian; Pe, Jönsson; Lagerlöf, B.; Lindholm, Christer; Ringborg, Ulrik; Westman, Gunnar; Östrup, Leif T.

doi:10.1200/jco.1991.9.12.2091

Cited by 131 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consensus was achieved regarding data to be collected on patients with newly diagnosed cutaneous melanoma. Studies focused on excision margins, 1,2 head and neck melanomas, 3,4 chemotherapy, 5 and limb perfusion 6 have been published previously. Sweden, with 8.8 million inhabitants, is divided into 6 health care regions.…”

Section: Discussionmentioning

confidence: 99%

Invasive cutaneous malignant melanoma in Sweden, 1990–1999

Lindholm¹,

Andersson²,

Dufmats³

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUND The objective of the current study was to compile prospective, population‐based data on cutaneous invasive melanomas in Sweden during the period from 1990 to 1999, to describe and analyze survival data and prognostic factors, and to make comparisons with previously published Swedish and international data. METHODS Twelve thousand five hundred thirty‐three patients, which included 97% of all registered melanomas in Sweden, were included and described. Among these, 9515 patients with clinical Stage I and II melanoma were included in an analysis of survival and in a univariate analysis, and 6191 patients were included in a multivariate analysis of prognostic factors. RESULTS There was no significant change in melanoma incidence during 1990–1999. Favorable prognostic factors were found, especially in younger and female patients, resulting in a relative 5‐year survival rate of 91.5%. In the multivariate analysis, significant factors that had a negative effect on survival were Clark level of invasion, Breslow thickness, ulceration, older patient age, trunk location, greatest tumor dimension, nodular histogenetic type, and male gender. CONCLUSIONS During the period from 1990 to 1999, the 5‐year survival of patients with malignant melanoma in Sweden was better compared with the previously reported rates in published, population‐based studies from Sweden, probably as a result of better secondary prevention due to better knowledge and awareness by both patients and the medical profession. The more favorable prognostic factors and the change in melanoma location found in younger patients, compared with earlier reports, may reflect changes in clothing as well as tanning habits; however, a decrease also was found in Clark Level II and thin melanomas for the same patient group. The authors concluded that further improvements can be achieved with better access to health care and with the use of early melanoma detection campaigns. Cancer 2004. © 2004 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Invasive cutaneous malignant melanoma in Sweden, 1990–1999

Lindholm¹,

Andersson²,

Dufmats³

et al. 2004

Cancer

View full text Add to dashboard Cite

show abstract

“…Survival rate was also significantly (p B0.01) improved after perfusion. In the Swedish study 17% remained recurrencefree after surgery alone in contrast to 30% in the perfused group (97). Tumour-free survival was significantly improved (p =0.044), but there was no difference in survival among a total of 69 patients.…”

Section: Malignant Melanomamentioning

confidence: 99%

“…for the lower and 0.45-1.0 mg/kg b.w. for the upper extremity) for 60 min as an adjuvant therapy after surgery (95)(96)(97). The German study was prematurely closed due to an improved disease-free survival in the perfused group: Overall, 6 out of 53 (11%) patients in the perfused group recurred, against 26 out of 56 (49%) in the surgery alone group (p B 0.001) (96).…”

Section: Malignant Melanomamentioning

confidence: 99%

Status of Clinical Hyperthermia

Dahl

Dalene²,

Bc³

et al. 1999

Acta Oncologica

View full text Add to dashboard Cite

“…Also a national randomized phase 111 study of 69 patients. where hyperthermic perfusion with melphalan was compared with surgery alone, showed a significantly improved tuniourfree survival in the combined treatment group (16). After moving to Gothenborg, Hafstrom extendcd his experimental work to perfusion of human liver tumours ( 17).…”

Section: Swedenmentioning

confidence: 99%

A Century With Hyperthermic Oncology In Scandinavia

Dahl

Overgaard

1995

Acta Oncologica

View full text Add to dashboard Cite

The hyperthermic research during the last 100 years is reviewed with the aim to describe a research activity which has been performed in parallel to and associated with the development of radiation oncology. Basic and clinical research in several Scandinavian centres has made major international contributions to the establishment of a rationale for and implementation of hyperthermia as a combined modality treatment together with chemotherapy or radiation in oncology. At the same time it has been demonstrated that collaboration and integration easily could be performed within the Scandinavian centres. Hyperthermic oncology is therefore a typical example of how research involving both biological, PhysicaUengineering, and clinical skills in a proper environment can create valuable results.

show abstract

Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.

Cited by 131 publications

References 0 publications

Invasive cutaneous malignant melanoma in Sweden, 1990–1999

Invasive cutaneous malignant melanoma in Sweden, 1990–1999

Status of Clinical Hyperthermia

A Century With Hyperthermic Oncology In Scandinavia

Contact Info

Product

Resources

About